Evidence map›Paper›PMID 41646475›Full record

ArticleESMO gastrointestinal oncology2025

Molecular analysis in pancreatic adenocarcinoma: a real-world study from high-volume French centres (CAPANCOBIO study).

C Evrard, M Brugel, G Piessen, G Roth, N Williet, V Hautefeuille, H Trelohan, M Muller, O Bouché, D Tougeron

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

C EvrardMedical Oncology Department, Poitiers University Hospital, Poitiers, France.
M BrugelGastroenterology and Digestive Oncology Department, Centre Hospitalier Côte Basque, Bayonne, France.
G PiessenDigestive and Oncological Surgery Department, CHRU Lille, CANTHER Laboratory Inserm UMR-S1277, University of Lille, Lille, France.
G RothDigestive Oncology and Hepatogastroenterology Department, CHU Grenoble-Alpes, Grenoble-Alpes University, Grenoble, France.
N WillietHepatogastroenterology Department, CHU Saint Etienne, Saint-Priest-en-Jarez, France.
V HautefeuilleDigestive Oncology and Gastroenterology Department, CHU Amiens-Picardie, Amiens, France.
H TrelohanOncology Department, GH La Rochelle, La Rochelle, France.
M MullerDepartment of Hepato-Gastroenterology and Inserm U1256, University Hospital of Nancy, Lorraine University, Vandoeuvre-lès-Nancy, France.
O BouchéUniversity of Reims Champagne-Ardenne (URCA), Digestive Oncology and Hepatogastroenterology Department, CHU Reims, Reims, France.
D TougeronHepato-Gastroenterology Department, Poitiers University Hospital, Poitiers, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In pancreatic adenocarcinoma (PA) it is crucial to better understand the molecular biology and identify targetable molecular alterations to obtain therapeutic improvements. Methods: The aim of the CAPANCOBIO study was to assess routine clinical practice regarding tumour somatic molecular analysis (SMA) in patients with unresectable PA. Tumour SMAs for patients with advanced PA were collected in nine high-volume French centres from September 2019 to October 2021 to identify factors influencing the prescription of SMA. Results: Among the 397 patients included in the CAPANCOBIO study, 70 had an SMA (17.6%). The most frequent tests were next-generation sequencing analysis (70.0%). Among the 70 patients with SMA, 31 (44.3%) had at least one alteration detected, but only 6 patients had targetable alterations. Among these, only one patient ( Conclusions: Few patients with advanced PA had SMA of the tumour. Despite patients with targetable molecular alterations identified, very few patients were treated with targeted therapy and/or included in a clinical trial. It is essential to increase SMA for advanced PA in routine clinical practice to increase the use of targeted therapy and inclusions in clinical trials.

Indexed as

molecular analysispancreatic adenocarcinomatargeted therapy

Identifiers

PMID41646475
PMCPMC12836571

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.